Enhertu Receives FDA Approval for New Indications
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy AZN?
Source: Newsfilter
- New Indication Approval: Enhertu has received FDA approval for use in neoadjuvant and adjuvant settings for HER2 positive early breast cancer, marking its significant role in curative-intent settings and reinforcing its application across stages of HER2 positive breast cancer.
- Clinical Trial Results: In the DESTINY-Breast11 trial, Enhertu combined with THP achieved a pathological complete response rate of 67.3%, significantly higher than the 56.3% in the control group, indicating its efficacy in high-risk early breast cancer patients.
- Survival Rate Improvement: The DESTINY-Breast05 trial demonstrated that Enhertu significantly reduced the risk of invasive disease recurrence or death, with a three-year invasive disease-free survival rate of 92.4%, showcasing its potential in postoperative treatment.
- Broad Market Prospects: This FDA approval expands Enhertu's indications to nine, expected to drive sales growth in the U.S. market, with AstraZeneca obligated to pay Daiichi Sankyo $155 million in milestone payments, further strengthening their collaboration in oncology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AZN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to rise
14 Analyst Rating
13 Buy
0 Hold
1 Sell
Strong Buy
Current: 184.960
Low
157.61
Averages
213.64
High
252.18
Current: 184.960
Low
157.61
Averages
213.64
High
252.18
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Enhertu Receives FDA Approval for New Indications
- New Indication Approval: Enhertu has received FDA approval for use in neoadjuvant and adjuvant settings for HER2 positive early breast cancer, marking its significant role in curative-intent settings and reinforcing its application across stages of HER2 positive breast cancer.
- Clinical Trial Results: In the DESTINY-Breast11 trial, Enhertu combined with THP achieved a pathological complete response rate of 67.3%, significantly higher than the 56.3% in the control group, indicating its efficacy in high-risk early breast cancer patients.
- Survival Rate Improvement: The DESTINY-Breast05 trial demonstrated that Enhertu significantly reduced the risk of invasive disease recurrence or death, with a three-year invasive disease-free survival rate of 92.4%, showcasing its potential in postoperative treatment.
- Broad Market Prospects: This FDA approval expands Enhertu's indications to nine, expected to drive sales growth in the U.S. market, with AstraZeneca obligated to pay Daiichi Sankyo $155 million in milestone payments, further strengthening their collaboration in oncology.
See More
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- Significant Partnership: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with Hengrui Pharma, aiming to co-develop around a dozen drugs, including four that Bristol will send to China for early-stage clinical trials, marking a new phase of international collaboration in drug development.
- Shift in R&D Model: This collaboration represents a departure from traditional licensing agreements, as both companies will contribute resources to drug development, positioning China as a vital part of the global pharmaceutical R&D ecosystem and highlighting U.S. drugmakers' increasing focus on the Chinese market.
- Market Trend Shift: According to DealForma, over half of large pharmaceutical licensing deals this year have originated from China, up from 39% last year, indicating a growing trend among U.S. and European biopharmaceutical companies to shift early drug development to China to expedite market entry.
- Future Industry Outlook: Experts predict that early-stage drug discovery will increasingly move to China due to its ability to conduct studies at lower costs and faster timelines, potentially reshaping the U.S. pharmaceutical landscape and encouraging more companies to initiate early clinical trials in China.
See More
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- New Drug Collaboration: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with China's Hengrui Pharma to jointly develop about a dozen drugs, including four experimental drugs that will be sent to China for early clinical trials, marking a new phase in cross-continental drug development.
- Significance of the Chinese Market: According to DealForma, over half of large pharmaceutical companies' licensing deals have originated from China this year, a significant increase from 39% last year, indicating a growing focus of American and European biopharmaceutical companies on the Chinese market, which could accelerate the introduction of new drugs.
- Shift in R&D Model: This partnership not only involves sending experimental drugs to China for development but also positions China as a crucial part of the global R&D ecosystem, reflecting the pharmaceutical industry's recognition of China's innovative capabilities and potentially altering the future landscape of drug development.
- Signal of Industry Transformation: As more companies conduct early drug development in China, industry experts believe this will enhance drug development efficiency and reduce costs, potentially challenging the traditional U.S. early drug discovery model and prompting global pharmaceutical companies to reassess their R&D strategies.
See More
AstraZeneca's Imfinzi Shows Significant Survival Benefits in Bladder Cancer Treatment
- Clinical Trial Results: AstraZeneca's Imfinzi combined with enfortumab vedotin demonstrated statistically significant improvements in event-free and overall survival in muscle-invasive bladder cancer patients, indicating its potential advantages in treatment.
- Comparison to Standard Therapy: Patients undergoing radical cystectomy who received Imfinzi showed significantly improved survival rates compared to standard treatment, underscoring the drug's importance in clinical applications.
- International Approval Status: Imfinzi is approved in over 40 countries for cisplatin-eligible muscle-invasive bladder cancer patients, reflecting its broad recognition in the global market.
- Future Research Directions: Imfinzi is also being investigated in the NILE Phase III trial for locally advanced or metastatic disease, suggesting further development potential in the bladder cancer treatment landscape.
See More
PRIMECAP Management's Q1 2026 Investment Strategy Insights
- Portfolio Overview: As of Q1 2026, PRIMECAP Management's portfolio consists of 320 stocks, with Eli Lilly representing 6.68%, indicating a strong positioning in the healthcare sector and reflecting confidence in long-term growth potential in this industry.
- Key Stock Increases: PRIMECAP increased its stake in Adobe Inc by 1,054,640 shares, bringing total holdings to 4,730,846 shares, representing a 28.69% increase, which suggests a positive outlook on Adobe's future growth and a significant contribution to its portfolio value.
- Reduction Analysis: Among 177 stocks, PRIMECAP reduced its position in Micron Technology by 2,920,732 shares, resulting in an 11.78% decrease, indicating a cautious stance on the stock's short-term performance, which may impact future returns.
- Complete Exits: PRIMECAP fully exited 8 holdings in Q1 2026, including 36,915,261 shares of AstraZeneca, resulting in a -2.57% impact on the portfolio, reflecting the firm's strategy adjustment in response to market changes.
See More
Foreign Healthcare Stocks Show Strong Quant Ratings
- Top Quant Ratings: Jazz Pharmaceuticals (JAZZ) leads with a 4.86 Quant score, showcasing its strong competitive position as one of the highest-rated specialty pharma companies globally, driven by a diversified neuroscience and oncology portfolio.
- Pipeline Excellence: AstraZeneca (AZN) follows closely with a 4.75 rating, reflecting the UK giant's exceptional pipeline execution and its status as one of the few mega-cap pharma companies currently favored by the Quant system.
- Focus on Specialty Drugs: Japanese pharma Astellas (ALPMY) and Swedish Orphan Biovitrum (SWOBY) round out the top four with scores of 4.64 and 4.63, respectively, highlighting the significance of specialty and orphan drug pipelines in the foreign healthcare sector's appeal.
- Market Disparity: While the top four stocks excel, Sandoz (SDZNY) and Galderma (GALDY) sit lower on the list with scores of 3.35, serving as a reminder that not all foreign healthcare stocks receive equal treatment from the Quant system, indicating a clear market disparity.
See More
Enhertu Receives FDA Approval for New Indications
- New Indication Approval: Enhertu has received FDA approval for use in neoadjuvant and adjuvant settings for HER2 positive early breast cancer, marking its significant role in curative-intent settings and reinforcing its application across stages of HER2 positive breast cancer.
- Clinical Trial Results: In the DESTINY-Breast11 trial, Enhertu combined with THP achieved a pathological complete response rate of 67.3%, significantly higher than the 56.3% in the control group, indicating its efficacy in high-risk early breast cancer patients.
- Survival Rate Improvement: The DESTINY-Breast05 trial demonstrated that Enhertu significantly reduced the risk of invasive disease recurrence or death, with a three-year invasive disease-free survival rate of 92.4%, showcasing its potential in postoperative treatment.
- Broad Market Prospects: This FDA approval expands Enhertu's indications to nine, expected to drive sales growth in the U.S. market, with AstraZeneca obligated to pay Daiichi Sankyo $155 million in milestone payments, further strengthening their collaboration in oncology.
See More
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- Significant Partnership: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with Hengrui Pharma, aiming to co-develop around a dozen drugs, including four that Bristol will send to China for early-stage clinical trials, marking a new phase of international collaboration in drug development.
- Shift in R&D Model: This collaboration represents a departure from traditional licensing agreements, as both companies will contribute resources to drug development, positioning China as a vital part of the global pharmaceutical R&D ecosystem and highlighting U.S. drugmakers' increasing focus on the Chinese market.
- Market Trend Shift: According to DealForma, over half of large pharmaceutical licensing deals this year have originated from China, up from 39% last year, indicating a growing trend among U.S. and European biopharmaceutical companies to shift early drug development to China to expedite market entry.
- Future Industry Outlook: Experts predict that early-stage drug discovery will increasingly move to China due to its ability to conduct studies at lower costs and faster timelines, potentially reshaping the U.S. pharmaceutical landscape and encouraging more companies to initiate early clinical trials in China.
See More
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development
- New Drug Collaboration: Bristol Myers Squibb has announced a potential multi-billion dollar partnership with China's Hengrui Pharma to jointly develop about a dozen drugs, including four experimental drugs that will be sent to China for early clinical trials, marking a new phase in cross-continental drug development.
- Significance of the Chinese Market: According to DealForma, over half of large pharmaceutical companies' licensing deals have originated from China this year, a significant increase from 39% last year, indicating a growing focus of American and European biopharmaceutical companies on the Chinese market, which could accelerate the introduction of new drugs.
- Shift in R&D Model: This partnership not only involves sending experimental drugs to China for development but also positions China as a crucial part of the global R&D ecosystem, reflecting the pharmaceutical industry's recognition of China's innovative capabilities and potentially altering the future landscape of drug development.
- Signal of Industry Transformation: As more companies conduct early drug development in China, industry experts believe this will enhance drug development efficiency and reduce costs, potentially challenging the traditional U.S. early drug discovery model and prompting global pharmaceutical companies to reassess their R&D strategies.
See More
AstraZeneca's Imfinzi Shows Significant Survival Benefits in Bladder Cancer Treatment
- Clinical Trial Results: AstraZeneca's Imfinzi combined with enfortumab vedotin demonstrated statistically significant improvements in event-free and overall survival in muscle-invasive bladder cancer patients, indicating its potential advantages in treatment.
- Comparison to Standard Therapy: Patients undergoing radical cystectomy who received Imfinzi showed significantly improved survival rates compared to standard treatment, underscoring the drug's importance in clinical applications.
- International Approval Status: Imfinzi is approved in over 40 countries for cisplatin-eligible muscle-invasive bladder cancer patients, reflecting its broad recognition in the global market.
- Future Research Directions: Imfinzi is also being investigated in the NILE Phase III trial for locally advanced or metastatic disease, suggesting further development potential in the bladder cancer treatment landscape.
See More
PRIMECAP Management's Q1 2026 Investment Strategy Insights
- Portfolio Overview: As of Q1 2026, PRIMECAP Management's portfolio consists of 320 stocks, with Eli Lilly representing 6.68%, indicating a strong positioning in the healthcare sector and reflecting confidence in long-term growth potential in this industry.
- Key Stock Increases: PRIMECAP increased its stake in Adobe Inc by 1,054,640 shares, bringing total holdings to 4,730,846 shares, representing a 28.69% increase, which suggests a positive outlook on Adobe's future growth and a significant contribution to its portfolio value.
- Reduction Analysis: Among 177 stocks, PRIMECAP reduced its position in Micron Technology by 2,920,732 shares, resulting in an 11.78% decrease, indicating a cautious stance on the stock's short-term performance, which may impact future returns.
- Complete Exits: PRIMECAP fully exited 8 holdings in Q1 2026, including 36,915,261 shares of AstraZeneca, resulting in a -2.57% impact on the portfolio, reflecting the firm's strategy adjustment in response to market changes.
See More
Foreign Healthcare Stocks Show Strong Quant Ratings
- Top Quant Ratings: Jazz Pharmaceuticals (JAZZ) leads with a 4.86 Quant score, showcasing its strong competitive position as one of the highest-rated specialty pharma companies globally, driven by a diversified neuroscience and oncology portfolio.
- Pipeline Excellence: AstraZeneca (AZN) follows closely with a 4.75 rating, reflecting the UK giant's exceptional pipeline execution and its status as one of the few mega-cap pharma companies currently favored by the Quant system.
- Focus on Specialty Drugs: Japanese pharma Astellas (ALPMY) and Swedish Orphan Biovitrum (SWOBY) round out the top four with scores of 4.64 and 4.63, respectively, highlighting the significance of specialty and orphan drug pipelines in the foreign healthcare sector's appeal.
- Market Disparity: While the top four stocks excel, Sandoz (SDZNY) and Galderma (GALDY) sit lower on the list with scores of 3.35, serving as a reminder that not all foreign healthcare stocks receive equal treatment from the Quant system, indicating a clear market disparity.
See More
